Highlights • The risks and benefits of ocrelizumab use in older progressive MS patients are not known • Age-related factors may contribute to disability, disease progression, and drug tolerability • Older progressive MS patients on ocrelizumab trend towards decreased disability progression • Ocrelizumab is generally safe and well tolerated in the older progressive MS subpopulation ABSTRACT Background Seminal trials evaluating anti-CD20 therapy in progressive MS primarily found benefit in...
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Libby
Contact Libby, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack